168 related articles for article (PubMed ID: 24587725)
1. Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.
Mishra T; Shrivastav PS
ScientificWorldJournal; 2014; 2014():482693. PubMed ID: 24587725
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics.
Reddy AV; Jaafar J; Aris AB; Majid ZA; Umar K; Talib J; Madhavi G
J Sep Sci; 2015 Aug; 38(15):2580-7. PubMed ID: 25989063
[TBL] [Abstract][Full Text] [Related]
3. Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects.
Yadav M; Rao R; Kurani H; Singhal P; Goswami S; Shrivastav PS
J Pharm Biomed Anal; 2009 May; 49(4):1115-22. PubMed ID: 19282124
[TBL] [Abstract][Full Text] [Related]
4. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Huang J; Gautam N; Bathena SP; Roy U; McMillan J; Gendelman HE; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2332-8. PubMed ID: 21752731
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Boffito M; Jackson A; Amara A; Back D; Khoo S; Higgs C; Seymour N; Gazzard B; Moyle G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4218-23. PubMed ID: 21709075
[TBL] [Abstract][Full Text] [Related]
6. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Deeks ED
Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
Sekar VJ; Lefebvre E; De Marez T; Spinosa-Guzman S; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Drugs R D; 2007; 8(4):241-8. PubMed ID: 17596110
[TBL] [Abstract][Full Text] [Related]
8. Quality control of protease inhibitors.
Yekkala R; Adams E; Van Schepdael A; Hoogmartens J
J Pharm Sci; 2008 Jun; 97(6):2012-21. PubMed ID: 17828738
[TBL] [Abstract][Full Text] [Related]
9. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
[TBL] [Abstract][Full Text] [Related]
10. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
11. Quantification of cell-associated atazanavir, darunavir, lopinavir, ritonavir, and efavirenz concentrations in human mononuclear cell extracts.
Podany AT; Winchester LC; Robbins BL; Fletcher CV
Antimicrob Agents Chemother; 2014 May; 58(5):2866-70. PubMed ID: 24614370
[TBL] [Abstract][Full Text] [Related]
12. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
ter Heine R; Alderden-Los CG; Rosing H; Hillebrand MJ; van Gorp EC; Huitema AD; Beijnen JH
Rapid Commun Mass Spectrom; 2007; 21(15):2505-14. PubMed ID: 17610214
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
[TBL] [Abstract][Full Text] [Related]
14. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
15. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.
Colombo S; Guignard N; Marzolini C; Telenti A; Biollaz J; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Oct; 810(1):25-34. PubMed ID: 15358304
[TBL] [Abstract][Full Text] [Related]
16. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Elens L; Veriter S; Di Fazio V; Vanbinst R; Boesmans D; Wallemacq P; Haufroid V
Clin Chem; 2009 Jan; 55(1):170-4. PubMed ID: 19028822
[TBL] [Abstract][Full Text] [Related]
17. Application of a validated ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of darunavir in human plasma for a bioequivalence study in Indian subjects.
Gupta A; Singhal P; Shrivastav PS; Sanyal M
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2443-53. PubMed ID: 21788160
[TBL] [Abstract][Full Text] [Related]
18. Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.
Poirier JM; Robidou P; Jaillon P
Ther Drug Monit; 2005 Apr; 27(2):186-92. PubMed ID: 15795650
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS.
Das Mishra T; Kurani H; Singhal P; Shrivastav PS
J Chromatogr Sci; 2012 Aug; 50(7):625-35. PubMed ID: 22562821
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
